ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

R. L. Coleman; K. Fujiwara; J. Sehouli; V. Salutari; P. Zola; R. Madry; J. Korach; P. Pautier; D. Cibula; S. Lheureux; K. Hasegawa; B. G. Kim; Chyong-Huey Lai; A. Gonzalez-Martinez; Q. Liu; S. Keefe; M. Puglisi; S. Topuz; B. J. Monk; R. C. Arend; D. M. O'Malley; I. Vergote

doi:10.1016/j.ygyno.2020.05.070

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

R. L. Coleman, K. Fujiwara, J. Sehouli, V. Salutari, P. Zola, R. Madry, J. Korach, P. Pautier, D. Cibula, S. Lheureux, K. Hasegawa, B. G. Kim, Chyong-Huey Lai, A. Gonzalez-Martinez, Q. Liu, S. Keefe, M. Puglisi, S. Topuz, B. J. Monk, R. C. ArendD. M. O'Malley, I. Vergote

醫學系

研究成果: 期刊稿件 › 文章 › 同行評審

原文	美式英語
頁（從 - 到）	89-90
期刊	Gynecologic Oncology
卷	159
DOIs	https://doi.org/10.1016/j.ygyno.2020.05.070
出版狀態	已出版 - 2020

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.ygyno.2020.05.070

引用此

Coleman, R. L., Fujiwara, K., Sehouli, J., Salutari, V., Zola, P., Madry, R., Korach, J., Pautier, P., Cibula, D., Lheureux, S., Hasegawa, K., Kim, B. G., Lai, C.-H., Gonzalez-Martinez, A., Liu, Q., Keefe, S., Puglisi, M., Topuz, S., Monk, B. J., ... Vergote, I. (2020). ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer. Gynecologic Oncology, 159, 89-90. https://doi.org/10.1016/j.ygyno.2020.05.070

@article{c9ba01053b0f46eeaeaa25a2dd7483cc,

title = "ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer",

author = "Coleman, {R. L.} and K. Fujiwara and J. Sehouli and V. Salutari and P. Zola and R. Madry and J. Korach and P. Pautier and D. Cibula and S. Lheureux and K. Hasegawa and Kim, {B. G.} and Chyong-Huey Lai and A. Gonzalez-Martinez and Q. Liu and S. Keefe and M. Puglisi and S. Topuz and Monk, {B. J.} and Arend, {R. C.} and O'Malley, {D. M.} and I. Vergote",

year = "2020",

doi = "10.1016/j.ygyno.2020.05.070",

language = "American English",

volume = "159",

pages = "89--90",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Coleman, RL, Fujiwara, K, Sehouli, J, Salutari, V, Zola, P, Madry, R, Korach, J, Pautier, P, Cibula, D, Lheureux, S, Hasegawa, K, Kim, BG, Lai, C-H, Gonzalez-Martinez, A, Liu, Q, Keefe, S, Puglisi, M, Topuz, S, Monk, BJ, Arend, RC, O'Malley, DM & Vergote, I 2020, 'ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer', Gynecologic Oncology, 卷 159, 頁 89-90. https://doi.org/10.1016/j.ygyno.2020.05.070

TY - JOUR

T1 - ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

AU - Coleman, R. L.

AU - Fujiwara, K.

AU - Sehouli, J.

AU - Salutari, V.

AU - Zola, P.

AU - Madry, R.

AU - Korach, J.

AU - Pautier, P.

AU - Cibula, D.

AU - Lheureux, S.

AU - Hasegawa, K.

AU - Kim, B. G.

AU - Lai, Chyong-Huey

AU - Gonzalez-Martinez, A.

AU - Liu, Q.

AU - Keefe, S.

AU - Puglisi, M.

AU - Topuz, S.

AU - Monk, B. J.

AU - Arend, R. C.

AU - O'Malley, D. M.

AU - Vergote, I.

PY - 2020

Y1 - 2020

U2 - 10.1016/j.ygyno.2020.05.070

DO - 10.1016/j.ygyno.2020.05.070

M3 - Journal Article

SN - 0090-8258

VL - 159

SP - 89

EP - 90

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -